P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences

Author(s): Mukesh Singh, Sasikanth Adigopula, Niaz Ahmad, Rohit Arora, Sandeep Khosla

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 6 , Issue 3 , 2011


Platelet activation and aggregation are key events in the pathophysiological process of thrombosis, and vascular occlusions. Antiplatelet therapy has proven to be crucial for managing patients with acute coronary syndromes, coronary artery disease and in patients undergoing percutaneous coronary interventions. However, residual platelet reactivity on antiplatelet treatment confers a five-fold increased risk of major adverse cardiovascular events which indicates a need for more effective antiplatelet medications to address the substantial burden of cardiovascular disease. This article reviews the P2Y12 receptor antagonists with regards to pharmacologic and pharmacogenetic differences and their clinical implications along with the discussion of recent patents.

Keywords: Antiplatelet therapy, novel agents, P2Y12 antagonists, Cyclo-oxygenase inhibitors, Thrombin Receptor Inhibition, Thromboxane Receptor Inhibitors, Serotonin receptor blockers, Glycoprotein VI antagnoists, Signaling Pathways Inhibitors, GPIIbIIIa Inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [207 - 214]
Pages: 8
DOI: 10.2174/157489011797376960
Price: $65

Article Metrics

PDF: 6